Physician profile
Daniel Perez
NPI 1174594527
$26,653.25
in general payments reported to CMS, 2019-2025
49 companies · $3,131 in 2025
The $3,131 reported for 2025 was more than what 88% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,863 · 2020: $2,983 · 2021: $3,297 · 2022: $2,496 · 2023: $7,592 · 2024: $4,292 · 2025: $3,131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,144 · Consulting Fee: $4,690 · Travel and Lodging: $965 · Long Term Medical Supply Or Device Loan: $181 · Education: $34.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,144.31 |
| Consulting Fee | $4,690.00 |
| Travel and Lodging | $964.95 |
| Long Term Medical Supply Or Device Loan | $181.16 |
| Education | $34.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $11,859.10 | 2019-2025 | Dovato, Cabenuva, Rukobia |
| Gilead Sciences, INC. | $3,583.52 | 2019-2025 | Biktarvy |
| Janssen Biotech, INC. | $2,373.22 | 2019-2023 | Symtuza, Prezcobix |
| Merck Sharp & Dohme LLC | $1,644.69 | 2019-2025 | Pifeltro, Delstrigo, Dificid |
| Insmed, INC. | $938.64 | 2019-2025 | Arikayce |
| Abbvie INC. | $668.75 | 2020-2025 | |
| Amgen INC. | $629.36 | 2019-2025 | Repatha, Otezla, Repatha |
| Paratek Pharmaceuticals, INC. | $626.24 | 2019-2025 | Nuzyra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $513.33 | 2019-2025 | Xifaxan |
| Emd Serono, INC. | $409.04 | 2019-2023 | Serostim |
| Janssen Products, Lp | $313.94 | 2019-2023 | Symtuza |
| Pfizer INC. | $286.72 | 2019-2025 | |
| Theratechnologies INC. | $284.08 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $271.92 | 2019-2022 | |
| Allergan, INC. | $196.80 | 2019-2020 |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $181.16 | 2025 | Integra |
| Exact Sciences Corporation | $159.95 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Cipla USA INC. | $142.37 | 2021 | |
| Medtronic, INC. | $140.00 | 2024 | |
| Aimmune Therapeutics, INC. | $134.65 | 2024-2025 | Zenpep, Vowst |
| Lilly USA, LLC | $124.84 | 2021-2025 | Zepbound, Mounjaro |
| Idorsia Pharmaceuticals US INC | $120.04 | 2023-2025 | Quviviq, Quviviq |
| Novartis Pharmaceuticals Corporation | $119.19 | 2024-2025 | |
| Glaxosmithkline, LLC. | $118.33 | 2020-2024 | Arexvy |
| Novo Nordisk INC | $87.32 | 2023-2025 | Ozempic, Rybelsus |
| Astellas Pharma US INC | $76.46 | 2019-2025 | Izervay |
| Trilliant Surgical LLC. | $64.98 | 2025 | Minimally Invasive Bunion Plate, Left |
| Alcon Vision LLC | $53.30 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $50.02 | 2019-2024 | Breztri |
| Nabriva Therapeutics, Plc | $48.83 | 2021-2022 | |
| Optinose US, INC. | $48.46 | 2025 | |
| Melinta Therapeutics, LLC | $44.33 | 2022-2024 | Rezzayo |
| Esperion Therapeutics, INC. | $43.78 | 2021-2024 | Nexletol |
| Janssen Pharmaceuticals, INC | $28.48 | 2021 | |
| Dexcom, INC. | $28.02 | 2024 | Dexcom G6 Transmitter |
| Seqirus USA INC | $26.31 | 2025 | Fluad, Flucelvax |
| Actelion Pharmaceuticals US, INC. | $26.04 | 2021 | |
| La Jolla Pharmaceutical Company | $24.53 | 2021 | |
| Mylan Institutional INC. | $23.91 | 2019 | |
| Arbor Pharmaceuticals, INC. | $22.57 | 2020 | |
| Scpharmaceuticals INC. | $21.99 | 2023 | |
| Sanofi Pasteur INC. | $20.00 | 2025 | |
| Tetraphase Pharmaceuticals, INC. | $19.26 | 2019 | |
| Amarin Pharma, INC. | $18.97 | 2019 | |
| Mylan Pharmaceuticals INC. | $14.45 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $13.62 | 2019 | |
| Kerecis Limited | $7.74 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Perez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.